JP3102645B2 - Nutritional composition for nutritional support - Google Patents
Nutritional composition for nutritional supportInfo
- Publication number
- JP3102645B2 JP3102645B2 JP02275662A JP27566290A JP3102645B2 JP 3102645 B2 JP3102645 B2 JP 3102645B2 JP 02275662 A JP02275662 A JP 02275662A JP 27566290 A JP27566290 A JP 27566290A JP 3102645 B2 JP3102645 B2 JP 3102645B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- fatty acid
- nutritional
- composition
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は、外科的手術の前後、或いは内科的疾患のさ
い等において、栄養補給を必要とする対象者に補給する
薬剤的活性を有する栄養組成物に関する。Description: FIELD OF THE INVENTION The present invention relates to a nutritional composition having a pharmacological activity to supply a subject in need of nutritional supplementation before and after a surgical operation or during a medical condition. About.
技術的背景 従来、種々の栄養組成物が外科的領域及び内科的領域
で使用されている。この栄養組成物中には、脂質や蛋白
質等多くの栄養成分が含まれている。そのうち、脂質
は、極めて速やかに消化・吸収される中鎖脂肪酸トリグ
リセリドやリノール酸含量の高い大豆油、コーン油、サ
フラワー油等より構成されている。脂質の必須脂肪酸は
リノール酸が主体であり、リノール酸と同様にヒト体内
で生合成されない必須脂肪酸であるα−リノレイン酸は
ごく少量しか含まれていない。α−リノレイン酸のヒト
における欠乏症としては知覚異常等の神経症状や皮膚炎
が報告され、さらに、近年ω３系列（α−リノレイン酸
系）の脂肪酸とその代謝産物の生理機能が解明され、ω
−３系列代謝の出発物質であるα−リノレイン酸の役割
の重要性が認識されてきた。すなわち、α−リノレイン
酸やその代謝産物であるエイコサペンタエン酸及びドコ
サヘキサエン酸は血清脂質の改善や抗血栓作用、抗炎症
作用、降圧作用、免疫抑制作用、腫瘍転移の抑制傾向等
を示し、各種疾患の防止・改善効果に期待が寄せられて
いる。TECHNICAL BACKGROUND Conventionally, various nutritional compositions are used in the surgical and medical fields. This nutrient composition contains many nutrients such as lipids and proteins. Among them, the lipids are composed of medium-chain fatty acid triglyceride and soybean oil, corn oil, safflower oil and the like having a high linoleic acid content, which are digested and absorbed very quickly. Essential fatty acids of lipids are mainly linoleic acid, and like linoleic acid, α-linoleic acid, which is an essential fatty acid not biosynthesized in the human body, contains only a very small amount. As the deficiency of α-linoleic acid in humans, neurological symptoms such as paresthesia and dermatitis have been reported, and recently, the physiological functions of fatty acids of the ω3 series (α-linoleic acid system) and metabolites thereof have been elucidated.
The importance of the role of α-linoleic acid, a starting material for -3 series metabolism, has been recognized. That is, α-linoleic acid and its metabolites eicosapentaenoic acid and docosahexaenoic acid show improvement in serum lipids, antithrombotic action, anti-inflammatory action, antihypertensive action, immunosuppressive action, tendency to suppress tumor metastasis, etc. Expectations are being raised for the effects of preventing and improving this.
上述の如く、現在、市販の栄養組成物ではα−リノレ
イン酸含量が少なく、リノール酸のみに重点がおかれて
設計されているため、バランスがとれた組成物であると
は認めがたい。また、経管栄養法の進歩に伴い、外科手
術早期から栄養組成物の使用が可能となり、さらに在宅
経管栄養法の普及とともに、経管栄養剤の使用期間も長
期化してきており、ω３系脂肪酸／ω６系脂肪酸比のバ
ランスの良い栄養組成物が望まれている。As described above, currently, commercially available nutritional compositions have a low content of α-linoleic acid and are designed with emphasis only on linoleic acid, and therefore cannot be recognized as balanced compositions. In addition, with the advancement of tube feeding, it is possible to use the nutritional composition from the early stage of surgery, and furthermore, with the spread of home tube feeding, the use period of tube feeding has also been extended. There is a need for a nutritional composition with a good balance of fatty acid / ω6 fatty acid ratio.
たん白質はアミノ酸組成やたん白価、吸収性等を考慮
し、乳たん白質、大豆たん白質、卵たん白質等が用いら
れている。あるいは、これらの分解物またはアミノ酸も
しくはこれらの組合せも用いられている。大豆たん白質
もしくはその分解物或いは大豆たん白質と乳たん白質と
の組合せによる窒素源は血清脂質の改善作用、降圧作用
等が報告されている。また、血清脂質はリノール酸やα
−リノレン酸、エイコサペンタエン酸、ドコサヘキサエ
ン酸等の多価不飽和脂肪酸により改善されることは周知
の通りであり、たん白質など各種の窒素源と脂質との組
合せにより、薬理的活性を有する栄養組成物への期待が
寄せられている。For protein, milk protein, soy protein, egg protein, etc. are used in consideration of amino acid composition, protein value, absorbability and the like. Alternatively, these degradation products or amino acids or combinations thereof have also been used. It has been reported that a soybean protein or its degradation product, or a combination of a soybean protein and a dairy protein, has a serum lipid improving effect, a hypotensive effect and the like. In addition, serum lipids such as linoleic acid and α
-It is well known that it is improved by polyunsaturated fatty acids such as linolenic acid, eicosapentaenoic acid and docosahexaenoic acid, and a nutritional composition having pharmacological activity by combining various nitrogen sources such as proteins and lipids. Expectations are high for things.
他方、経口及び経管栄養において最も頻度の高い副作
用は下痢であり、特に手術施行後の施行例においては20
％前後に経験され、下痢は予想外に患者および医療従事
者を悩まている大きな問題となっている。このことか
ら、これまでの経口及び経管栄養組成物の開発目標は、
常に下痢発生の防止にあったと言っても過言ではない。On the other hand, the most frequent side effect of oral and tube feeding is diarrhea, especially in patients after surgery.
%, And diarrhea is a major problem that unexpectedly plagues patients and healthcare professionals. From this, the development goals of oral and tube feeding compositions so far are:
It is no exaggeration to say that we were always in the prevention of diarrhea.
栄養施行時に下痢が発生すれば、栄養組成物の注入速
度をおとす処置がとられ、最悪の場合には投与を中止せ
ざるを得ない。この場合、患者に必要充分な熱量を与え
られないために、非生理的とされる静脈栄養補給を行わ
ざるを得ない。従って、下痢の発生を抑える栄養組成物
の開発は早急に解決しなければならない課題である。If diarrhea occurs during nutrition, treatment for reducing the infusion rate of the nutritional composition is taken, and in the worst case, the administration must be stopped. In this case, since the patient cannot be provided with a necessary and sufficient amount of heat, parenteral vein feeding, which is regarded as non-physiological, must be performed. Therefore, the development of a nutritional composition that suppresses the occurrence of diarrhea is an issue that must be resolved immediately.
発明が解決しようとする課題 本発明者らは、下痢の発生頻度が低く、かつ薬剤的活
性を有する栄養組成物について鋭意検討を進めた結果、
栄養組成物中の脂質の脂肪酸としてα−リノレイン酸、
エイコサペンタエン酸、ドコサヘキサエン酸などのω３
系脂肪酸とリノール酸などω６系脂肪酸とを含む組成の
脂肪を用い、その比率をω３系脂肪酸／ω６系脂肪酸2/
1〜1/5とすると、血清脂肪酸のω３系脂肪酸／ω６系脂
肪酸比の低下を抑制し、下痢の発生を防止するなど多く
の薬剤的活性を有することを見出し、さらに、この活性
がたん白質として乳たん白質と大豆たん白質とを特定の
比率、すなわち乳たん白質／大豆たん白質1/3〜3/1とす
るといちじるしく高まることを見出した。本発明は、こ
れらの知見に基づいてなされたものである。Problems to be Solved by the Invention The present inventors have a low frequency of diarrhea, and as a result of intensive studies on nutritional compositions having pharmaceutical activity,
Α-linoleic acid as a fatty acid of the lipid in the nutritional composition,
Ω3 of eicosapentaenoic acid, docosahexaenoic acid, etc.
A fat having a composition containing a ω6 fatty acid such as a linoleic acid and a ω6 fatty acid is used, and the ratio thereof is ω3 fatty acid / ω6 fatty acid 2
If it is 1 to 1/5, it has been found that it has many pharmaceutical activities such as suppressing the decrease in the ratio of ω3 fatty acid / ω6 fatty acid in serum fatty acids and preventing the occurrence of diarrhea. It was found that when the ratio of milk protein and soy protein was set to a specific ratio, that is, milk protein / soy protein was set to 1/3 to 3/1, the increase was remarkable. The present invention has been made based on these findings.
すなわち、本発明は、外科的領域及び内科的領域等で
使用される薬剤的活性を有する経口経管栄養組成物を提
供することを課題とする。That is, an object of the present invention is to provide an oral tube-feeding composition having pharmacological activity used in a surgical field, a medical field, and the like.
課題を解決するための手段 本発明に係る栄養組成物は、特定の脂質及びたん白質
を一定の割合で組合せることを特徴とする。Means for Solving the Problems The nutritional composition according to the present invention is characterized by combining a specific lipid and a protein at a certain ratio.
すなわち、脂質として、中鎖脂肪酸０〜60％、ω３系
脂肪酸３〜20％及びω６系脂肪酸10〜40％を含み、ω３
系脂肪酸とω６系脂肪酸との比率がω３系脂肪酸／ω６
系脂肪酸2/1〜1/5である脂肪酸組成の脂質を使用する。
また、たん白質として、乳たん白質と大豆たん白質とよ
りなり、両者の比率が乳たん白質／大豆たん白質1/3〜3
/1のたん白質を使用する。That is, the fat contains 0 to 60% of medium-chain fatty acids, 3 to 20% of ω3 fatty acids, and 10 to 40% of ω6 fatty acids,
Ratio of ω6 fatty acid to ω6 fatty acid / ω6
A fatty acid having a fatty acid composition of 2/1 to 1/5 is used.
In addition, the protein consists of milk protein and soy protein, and the ratio of both is milk protein / soy protein 1/3 to 3
Use / 1 protein.
脂質は適応患者、特に、消化器外科手術後の患者は消
化吸収が著しく低下していることから、極めて速やかに
消化・吸収される中鎖脂肪酸トリグリセリドを用い、好
適には脂肪酸組成中カプリル酸を０〜60重量％含有さ
せ、さらに好ましくは20〜60重量％含有させる。これと
共に、ω３系脂肪酸、特に好ましくはα−リノレイン酸
３〜20％及びω６系脂肪酸、特に好ましくはリノール酸
を脂肪酸組成中10〜40重量％を有し、ω３系脂肪酸／ω
６系脂肪酸の比率は2/1〜1/5とする。ω３系脂肪酸はα
−リノレン酸、エイコサンペンタエン酸、ドコサヘキサ
エン酸より選ばれるものであり、ω６系脂肪酸はリノー
ル酸である。本発明ではこれらの脂肪酸を含有する動植
物油脂を使用する。ω３系脂肪酸及びω６系脂肪酸を含
有する油としては、シソ油、エゴマ油、アマニ油、キリ
油、魚油、サフラワー油、コーン油、大豆油、ナタネ油
などの食用油を例示し得る。また所望のω３系脂肪酸／
ω６系脂肪酸比を得るためには、これらの２種又はそれ
以上の組合せより構成し得る。Lipids are indicated for patients, especially after gastrointestinal surgery, where digestion and absorption are significantly reduced, so use medium-chain fatty acid triglyceride, which is digested and absorbed very quickly, preferably caprylic acid in the fatty acid composition. 0 to 60% by weight, more preferably 20 to 60% by weight. Along with this, the ω3 fatty acid, particularly preferably 3 to 20% of α-linoleic acid and the ω6 fatty acid, particularly preferably linoleic acid, has 10 to 40% by weight in the fatty acid composition, and ω3 fatty acid / ω
The ratio of the 6-system fatty acid is 2/1 to 1/5. ω3 fatty acids are α
-Is selected from linolenic acid, eicosane pentaenoic acid and docosahexaenoic acid, and the ω6-based fatty acid is linoleic acid. In the present invention, animal and vegetable fats and oils containing these fatty acids are used. Examples of oils containing ω3 and ω6 fatty acids include edible oils such as perilla oil, perilla oil, linseed oil, kiri oil, fish oil, safflower oil, corn oil, soybean oil, and rapeseed oil. The desired ω3 fatty acid /
In order to obtain an ω6-based fatty acid ratio, it may be composed of a combination of two or more of these.
たん白質（窒素源）としては乳たん白質、大豆たん白
質、卵たん白質等及びその分解物、脂肪族アミノ酸、オ
キシアミノ酸、含硫アミノ酸、芳香族アミノ酸などの中
性、酸性及び塩基性アミノ酸を例示し得る。好ましく
は、消化・吸収がよく良質である乳たん白質及び大豆た
ん白質を用い、下痢の発生防止、便性の改善、薬理的活
性、循環器系疾患、慢性疾患の立場から、乳たん白質と
大豆たん白質の混合比率は1:3〜3:1とする。Proteins (nitrogen sources) include milk protein, soy protein, egg protein and their degradation products, neutral amino acids, acidic amino acids and basic amino acids such as aliphatic amino acids, oxy amino acids, sulfur-containing amino acids, and aromatic amino acids. Can be illustrated. Preferably, milk protein and soy protein, which are good in digestion and absorption, are used to prevent the occurrence of diarrhea, improve stool, pharmacological activity, circulatory disease, and chronic disease. The mixing ratio of soy protein is 1: 3 to 3: 1.
なお、本発明の組成物を構成する糖質としては、浸透
圧等をあげないためにデキストリン、蔗糖、グルコー
ス、ガラクトース、マルトース等を例示することがで
き、その他ミネラルとしはNa,K,Ca,Mg,P,Cl,Fe,Zn,Cu,M
n,I等を、また、ビタミンとしてはA,D,E,Kなどの脂溶性
ビタミンやB1,B2,B6,B12,C,パントテン酸、ニアシン、
ビオチン、葉酸等の水溶性ビタミンを例示し得る。In addition, as a saccharide constituting the composition of the present invention, dextrin, sucrose, glucose, galactose, maltose and the like can be exemplified in order not to increase osmotic pressure and the like, and other minerals such as Na, K, Ca, Mg, P, Cl, Fe, Zn, Cu, M
n, the I like, also fat-soluble vitamins and B 1, such as A, D, E, K as vitamins, B 2, B 6, B 12, C, pantothenic acid, niacin,
Examples include water-soluble vitamins such as biotin and folic acid.
本発明の栄養組成物は、粉末状、或いは液状であり、
状況に応じて経口又は経管で処方することができる。The nutritional composition of the present invention is in the form of powder or liquid,
It can be prescribed orally or by tube depending on the situation.
以下に実施例及び試験例を示して本発明をさらに具体
的に説明する。Hereinafter, the present invention will be described more specifically with reference to Examples and Test Examples.
（実施例） 実施例１ 下記配合組成の液状組成物を調製した。(Example) Example 1 A liquid composition having the following composition was prepared.
成分組成 g/100ml 酸カゼイン 3.85 分離大豆たん白質 1.29 デキストリン 16.16 大豆油 0.82 エゴマ油 0.16 中鎖脂肪酸トリグリセリド（MCT） 1.02 高純度大豆リン脂質 0.16 ミネラル類 0.60 ビタミン類 0.06 精製水 82.6 g この脂質の脂肪酸組成は、カプリル酸42.5％、α−リ
ノレン酸7.6％、リノール酸25.8％よりなり、ω３系脂
肪酸／ω６系脂肪酸は0.29であった。また、酸カゼイン
と分離大豆たん白質との比率は2.98であった。Ingredients g / 100ml acid casein 3.85 isolated soy protein 1.29 dextrin 16.16 soybean oil 0.82 perilla oil 0.16 medium-chain fatty acid triglyceride (MCT) 1.02 high-purity soybean phospholipid 0.16 minerals 0.60 vitamins 0.06 purified water 82.6 g fatty acid composition of this lipid Was composed of 42.5% of caprylic acid, 7.6% of α-linolenic acid, and 25.8% of linoleic acid, and the ratio of ω3 fatty acid / ω6 fatty acid was 0.29. The ratio of acid casein to isolated soybean protein was 2.98.
実施例２ 下記配合組成の粉末組成物を調製した。Example 2 A powder composition having the following composition was prepared.
成分組成 重量％ 酸カゼイン 5.39 分離大豆たん白質 16.17 メチオニン 0.31 デキストリン 66.14 大豆油 2.43 魚油濃縮物 2.53 パーム油 2.88 高純度大豆リン脂質 1.03 ミネラル類 3.00 ビタミン類 0.12 この脂質の脂肪酸組成は、カプリル酸痕跡、α−リノ
レン酸3.2％、リノール酸25.7％、エイコサペンタエン
酸7.7％、ドコサヘキサエン酸4.5％よりなり、ω３系脂
肪酸／ω６系脂肪酸は0.60であった。また酸カゼイン／
分離大豆たん白質は0.33であった。Ingredient composition% by weight acid casein 5.39 isolated soy protein 16.17 methionine 0.31 dextrin 66.14 soybean oil 2.43 fish oil concentrate 2.53 palm oil 2.88 high-purity soybean phospholipid 1.03 minerals 3.00 vitamins 0.12 The fatty acid composition of this lipid is traces of caprylic acid, α -Consisting of linolenic acid 3.2%, linoleic acid 25.7%, eicosapentaenoic acid 7.7% and docosahexaenoic acid 4.5%, and the ratio of ω3 fatty acid / ω6 fatty acid was 0.60. Acid casein /
The isolated soy protein was 0.33.
（試験例） 次に、本発明の栄養組成物の効果を試験例を用いて説
明する。(Test Example) Next, the effects of the nutritional composition of the present invention will be described using test examples.
Wistar系雄ラット（体重200g程度）を一晩絶食させ、
全身麻酔下で開腹し、小腸の約60％を切除した小腸切除
モデルを作成した。このラットに対して、試験栄養組成
物を1Kcal/1ml濃度で13日間経口投与して効果を試験し
た。Wistar male rats (weight about 200g) were fasted overnight,
A small intestine resection model in which the abdomen was opened under general anesthesia and about 60% of the small intestine was removed was created. The test nutritional composition was orally administered to the rat at a concentration of 1 Kcal / 1 ml for 13 days to test the effect.
試験に用いた組成物の100Kcal/100mlにおける組成を
表１に示した。栄養組成物（Ａ）は本発明の実施例１の
組成物であり、ω３系脂肪酸／ω６系脂肪酸比は10/33.
95である。栄養組成物（Ｂ）は、脂質が中鎖脂肪酸トリ
グリセリドと大豆油より構成され、ω３系脂肪酸／ω６
系脂肪酸の比率が0.14であり、窒素源は乳たん白質、乳
清たん白質、大豆たん白質である市販栄養剤である。栄
養組成物（Ｃ）は脂質がコーン油のみにより構成され、
ω３系脂肪酸／ω６系脂肪酸の比率が0.04であり、窒素
源はカゼインと、大豆たん白質よりなる市販栄養剤であ
る。なお、各試験栄養剤投与のラット匹数はそれぞれ８
匹ずつとした。Table 1 shows the composition of the composition used in the test at 100 Kcal / 100 ml. The nutritional composition (A) is the composition of Example 1 of the present invention, and the ratio of ω3 fatty acid / ω6 fatty acid is 10/33.
95. The nutritional composition (B) is composed of medium-chain fatty acid triglyceride and soybean oil, and contains ω3 fatty acid / ω6
The ratio of the system fatty acid is 0.14, and the nitrogen source is a commercial nutrient that is milk protein, whey protein, and soy protein. The nutrient composition (C) is composed of corn oil only as a lipid,
The ratio of ω3 fatty acid / ω6 fatty acid is 0.04, and the nitrogen source is a commercially available nutrient consisting of casein and soy protein. The number of rats to which each test nutrient was administered was 8
Each animal was used.
上記試験の結果図１〜図３に示した。 The results of the above test are shown in FIGS.
図１は、各栄養組成物の投与終了後の血清中の脂肪酸
分画におけるω３系脂肪酸（α−リノレイン酸、エイコ
サペンタエン酸及びドコサヘキサエン酸）とω６系脂肪
酸（リノール酸及びアラキドン酸）の比を示したもので
ある。本発明の栄養組成物である（Ａ）が、他の市販栄
養組成物（Ｂ）及び（Ｃ）に比較して、ω３系脂肪酸／
ω６系脂肪酸比が高値となった。これは、本発明の栄養
組成物（Ａ）が血清中の脂肪のω３系の脂肪酸／ω６系
脂肪酸比率の低下を抑制する効果を示すものである。FIG. 1 shows the ratio of ω3 fatty acids (α-linoleic acid, eicosapentaenoic acid and docosahexaenoic acid) to ω6 fatty acids (linoleic acid and arachidonic acid) in the fatty acid fraction in serum after the administration of each nutritional composition. It is shown. The nutritional composition (A) of the present invention is different from the other commercial nutritional compositions (B) and (C) in that the ω3 fatty acid /
The ω6 fatty acid ratio became high. This indicates that the nutritional composition (A) of the present invention has an effect of suppressing a decrease in the ratio of ω3-based fatty acids / ω6-based fatty acids in serum fat.
図２は栄養状態の指標として一般的に用いられている
血清中のアルブミン値を示したものである。本発明の栄
養組成物（Ａ）を投与した場合が他の栄養組成物（Ｂ）
及び（Ｃ）を投与した場合に比較して高値であり、これ
は本発明の栄養組成物（Ａ）が最も栄養価が高いことを
示すものである。FIG. 2 shows the albumin level in serum, which is generally used as an indicator of nutritional status. When the nutrition composition (A) of the present invention is administered, another nutrition composition (B) is administered.
And (C) are higher than those administered, indicating that the nutritional composition (A) of the present invention has the highest nutritional value.
図３は血清総コレステロールを示したものである。 FIG. 3 shows serum total cholesterol.
血清コレステロールの上昇は動脈硬化などの循環器系
疾患の発現因子の１つであると言われているが、今回、
栄養組成物（Ｃ）の投与によりコレステロール値は著明
に上昇した。一方、本発明の栄養組成物（Ａ）では上昇
はみられず、生理的範囲を維持し、上昇の抑制効果が認
められた。It is said that elevated serum cholesterol is one of the factors that cause circulatory diseases such as arteriosclerosis.
The administration of the nutritional composition (C) markedly increased the cholesterol level. On the other hand, no increase was observed in the nutritional composition (A) of the present invention, and the physiological range was maintained, and an effect of suppressing the increase was observed.
表２及び図４は各試験栄養組成物投与時における各日
の便性状の累積値を示したものである。本発明の栄養組
成物（Ａ）は、他の栄養剤（Ｂ）及び（Ｃ）に比較して
投与期間を通じて下痢の発生を抑制して便の性状が良好
であることが示された。Table 2 and FIG. 4 show the accumulated values of stool properties on each day when each test nutritional composition was administered. It was shown that the nutritional composition (A) of the present invention suppressed the occurrence of diarrhea throughout the administration period and had better stool properties as compared with the other nutrients (B) and (C).
上述の動物試験の結果から認められるように、外科手
術後を代表とする患者などに本発明の栄養組成物を投与
すると、血清中脂肪酸のω３系脂肪酸／ω６系脂肪酸比
の低下を防止し、さらに治療上、医療従事者が難渋する
下痢の発生を抑制し、栄養状態を良好に保つことが可能
となる。 As can be seen from the results of the above-described animal tests, administration of the nutritional composition of the present invention to a patient, typically after surgery, prevents a decrease in the ratio of ω3 fatty acids / ω6 fatty acids in serum fatty acids, Furthermore, it becomes possible to suppress the occurrence of diarrhea, which is difficult for medical staff during treatment, and to maintain a good nutritional state.
なお、実施例（２）の栄養組成物も同様な薬理的活性
を有することが確かめられた。In addition, it was confirmed that the nutritional composition of Example (2) also had a similar pharmacological activity.
【図面の簡単な説明】 図１は本発明（Ａ）並びに比較例（Ｂ）及び（Ｃ）の各
栄養組成物を投与した場合の血清中脂肪酸のω３系脂肪
酸／ω６系脂肪酸の比を示し、図２は同じく血清中アル
ブミン値、図３は血清コレステロール値を示したもので
ある。 図４は各栄養組成物の投与各日の便性の述べ累積パター
ンを示したものである。 図中、＊＊はｐ＜0.01、＊はｐ＜0.05を示す。BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows the ratio of ω3 fatty acid / ω6 fatty acid in serum fatty acids when each of the nutritional compositions of the present invention (A) and comparative examples (B) and (C) are administered. FIG. 2 shows the serum albumin level, and FIG. 3 shows the serum cholesterol level. FIG. 4 shows the cumulative pattern of the stool on each day of administration of each nutritional composition. In the figure, ** indicates p <0.01 and * indicates p <0.05.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ Ａ６１Ｋ 33/00 Ａ６１Ｋ 33/00 38/00 37/02 37/18 37/22 (72)発明者 前川 勉 栃木県下都賀郡石橋町大字下古山231 倉井マンション１―Ａ (72)発明者 山下 誠 栃木県宇都宮市江曽島町1438―１ (72)発明者 水口 恒夫 栃木県宇都宮市雀の宮７丁目２番18号 (56)参考文献 特開 平１−67164（ＪＰ，Ａ) 特開 昭58−189110（ＪＰ，Ａ) 特開 昭63−309162（ＪＰ，Ａ) 特開 平１−128919（ＪＰ，Ａ) 特開 平２−134326（ＪＰ，Ａ) 特開 平２−200165（ＪＰ，Ａ)──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification code FI A61K 33/00 A61K 33/00 38/00 37/02 37/18 37/22 (72) Inventor Tsutomu Maekawa Ishibashi, Shimotsuga-gun, Tochigi Prefecture 231 Shimokoyama, Kurashi-machi, Townhouse 1-A (72) Inventor Makoto Yamashita 144-1-1, Esojima-cho, Utsunomiya City, Tochigi Prefecture (72) Inventor Tsuneo Mizuguchi 7-18-18 Sparrow Palace, Utsunomiya City, Tochigi Prefecture (56) References JP-A-1-67164 (JP, A) JP-A-58-189110 (JP, A) JP-A-63-309162 (JP, A) JP-A-1-128919 (JP, A) JP-A-2-134326 ( JP, A) JP-A-2-200165 (JP, A)
Claims (3)
３系脂肪酸３〜20％及びω６系脂肪酸10〜40％を含み、
かつω３系脂肪酸／ω６系脂肪酸の比類が2/1〜1/5であ
る脂質、乳蛋白質と大豆蛋白質とよりなり両者の比率が
乳蛋白質／大豆蛋白質1/3〜3/1である蛋白質もしくはそ
の分解物あるいはアミノ酸、糖質、ミネラル及びビタミ
ンを主成分とする栄養補給用栄養組成物。(1) In the composition of fatty acids, 0-60% of medium chain fatty acids, ω
Contains 3-20% of tertiary fatty acids and 10-40% of ω6 fatty acids,
And a protein in which the ratio of ω3 fatty acid / ω6 fatty acid is 2/1 to 1/5, a protein comprising milk protein and soy protein, and the ratio of both is milk protein / soy protein 1/3 to 3/1 or A nutritional composition for nutritional supplements containing its decomposed products or amino acids, carbohydrates, minerals and vitamins as main components.
脂肪酸がα−リノレン酸、エイコサペンタエン酸、ドコ
サヘキサエン酸よりなる群から選択される少なくとも１
種の脂肪酸であり、ω６系脂肪酸がリノール酸である請
求項（１）に記載の栄養補給用栄養組成物。2. The medium chain fatty acid is caprylic acid, and the ω3 fatty acid is at least one selected from the group consisting of α-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid.
The nutritional composition for nutritional supplementation according to claim 1, wherein the ω6 fatty acid is linoleic acid.
肪酸がリノール酸である請求項（１）又は（２）に記載
の栄養補給用栄養組成物。3. The nutritional supplement composition according to claim 1, wherein the ω3 fatty acid is α-linolenic acid and the ω6 fatty acid is linoleic acid.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP02275662A JP3102645B2 (en) | 1990-10-15 | 1990-10-15 | Nutritional composition for nutritional support |
| KR1019910017618A KR100270622B1 (en) | 1990-10-15 | 1991-10-08 | A nutrition composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP02275662A JP3102645B2 (en) | 1990-10-15 | 1990-10-15 | Nutritional composition for nutritional support |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04152861A JPH04152861A (en) | 1992-05-26 |
| JP3102645B2 true JP3102645B2 (en) | 2000-10-23 |
Family
ID=17558599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP02275662A Expired - Lifetime JP3102645B2 (en) | 1990-10-15 | 1990-10-15 | Nutritional composition for nutritional support |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP3102645B2 (en) |
| KR (1) | KR100270622B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006033349A1 (en) | 2004-09-22 | 2006-03-30 | Ajinomoto Co., Inc. | Total enteral nutritious composition |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5308832A (en) * | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
| JPH07308147A (en) * | 1994-05-17 | 1995-11-28 | Nikken Food Kk | Antistress bread and its preparation |
| DE4417851C1 (en) * | 1994-05-20 | 1995-10-05 | Horst Heirler | Dietary food with medium-chain fatty acids and its use |
| JPH09121766A (en) * | 1995-10-31 | 1997-05-13 | Meiji Milk Prod Co Ltd | Food for infant having regulated n-6 series/n-3 series fatty acid ratio |
| CA2223198A1 (en) * | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| DE60130737T3 (en) | 2000-01-28 | 2016-01-14 | Dsm Ip Assets B.V. | Increased production of lipids containing polyunsaturated fatty acids by high density cultures of eukaryotic microbes in fermenters |
| EP1438378B1 (en) * | 2001-10-18 | 2011-10-26 | Council of Scientific and Industrial Research | Cholesterol lowering structured lipids with omega 6 pufa |
| JP2003313142A (en) * | 2002-02-20 | 2003-11-06 | En Otsuka Pharmaceutical Co Ltd | Nutritional composition |
| WO2008010472A1 (en) * | 2006-07-18 | 2008-01-24 | Ajinomoto Co., Inc. | Total enteral nutrition composition |
| JP6059007B2 (en) * | 2012-12-26 | 2017-01-11 | キユーピー株式会社 | Water-soluble powder component-dispersed high nutrition composition and method for producing the same |
-
1990
- 1990-10-15 JP JP02275662A patent/JP3102645B2/en not_active Expired - Lifetime
-
1991
- 1991-10-08 KR KR1019910017618A patent/KR100270622B1/en not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006033349A1 (en) | 2004-09-22 | 2006-03-30 | Ajinomoto Co., Inc. | Total enteral nutritious composition |
| US7790209B2 (en) | 2004-09-22 | 2010-09-07 | Ajinomoto Co., Inc. | Total enteral nutritious composition |
Also Published As
| Publication number | Publication date |
|---|---|
| KR920007634A (en) | 1992-05-27 |
| KR100270622B1 (en) | 2000-11-01 |
| JPH04152861A (en) | 1992-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5860704B2 (en) | Fish oil type parenteral nutrition emulsion fortified with omega-3 in water | |
| JP5574561B2 (en) | Total enteral nutrition composition | |
| US5886037A (en) | Nutritional composition for the treatment of hypertriglyceridaemia and hyperchylomicronaemia | |
| KR101424822B1 (en) | Nutritional supplement containing long-chain polyunsaturated fatty acids | |
| US9629386B2 (en) | Nutrition composition | |
| EP2528456B1 (en) | Liquid enteral nutritional composition suitable for tube feeding | |
| US5434183A (en) | Phospholipids containing omega-3-fatty acids | |
| EP1039892B1 (en) | Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis | |
| EP1337236B1 (en) | Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition | |
| CN1200654A (en) | Nutritional support of paediatric patients | |
| JP2010100655A (en) | Composition and method for treatment of gastro-intestinal tract of inflammatory condition | |
| JP3102645B2 (en) | Nutritional composition for nutritional support | |
| TW201735801A (en) | Nutritional products comprising beta-hydroxy-beta-methylbutyrate | |
| JPH0394655A (en) | Nutrient feeding composition | |
| JP4394174B2 (en) | Inflammatory bowel disease treatment | |
| JP4997514B2 (en) | Antihypertensive agent | |
| MXPA99007737A (en) | Use of polyunsaturated fatty acids forreducing the incidence of necrotizing enterocolitis | |
| JPS6049745A (en) | Oil and fat composition for food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100825 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110825 Year of fee payment: 11 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110825 Year of fee payment: 11 |